### 2023 CYSTIC FIBROSIS FOUNDATION PATIENT REGISTRY HIGHLIGHTS CYSTIC FIBROSIS FOUNDATION<sup>®</sup>

## **REGISTRY BY THE NUMBERS**











33,288 People in the Registry


100,648 Clinic Visits

12,569 Telehealth Visits

10,164 Hospitalizations


# LUNG FUNCTION

Lung function is a primary indicator of health for people with CF. FEV<sub>1</sub>, a measure of lung function, is the forced exhaled volume of air in the first second of an exhaled breath. It is shown as a percent predicted based on the  $FEV_1$  of healthy, non-smoking people of the same age, height, and gender.




# **EXACERBATIONS**

**PEOPLE WITH CF WITH ONE OR MORE PULMONARY EXACERBATION** Pulmonary exacerbations, when lung symptoms worsen, are common in people with CF. This graphic shows those treated with intravenous antibiotics. Two likely contributors to the decrease since 2019 include the additional attention to infection prevention and control related to the pandemic and the wide adoption of elexacaftor/tezacaftor/ivacaftor.



### **RACE AND ETHNICITY**

The CF population is growing more diverse every year. In 2023, over 17% percent of people with CF identified as either Hispanic, Black, multiracial, Asian or as other than white.



#### **IDENTIFYING CF EARLIER** MEDIAN AGE AT FIRST CF EVENT\*

2013: 24 days 2019: 22 days 2023: 21 days


\*Measure for timeliness inclusive of sweat test, clinic visit, and/or hospitalization

As Dr. Bruce Marshall steps into retirement in 2024, his legacy with the CF Foundation Patient Registry and contribution to CF care will continue to inspire and guide us.

# **MICROBIOLOGY**

	Bacteria	Percent With Infection	Median Age in Years at First Infection
	Pseudomonas aeruginosa	25%	5
	Stenotrophomonas maltophilia	5%	9
	Methicilin-resistant Staphylococcus aureus	14%	10
	Achromobacter xylosoxidans	2%	14
\$	Burkholderia cepacia complex	1%	20
XIII	Nontuberculous mycobacteria	10%	25

# **INSURANCE**



49% of adults with CF 18-25 years are on their parents' insurance plan.





13% of adults with CF 18-64 years are on Medicare.

38% of all people with CF are on Medicaid.





20

15

53% of children with CF under 10 years are on Medicaid.


## **20 YEARS OF PROGRESS**

2003

2023



**18 Years or Older** 2003: 8,518 2023: 20,107







10 16.6

**Annual Mortality Rate** (Per 1,000 People)

7.0

**FEV<sub>1</sub> Percent Predicted** (Median, individuals 7 years and older)






**Children on Inhaled Antibiotics** 


Adults on **Inhaled Antibiotics** 

# **CFTR MODULATORS**



## TRANSPLANTATION

In the Registry, there has been a dramatic decrease in the number of lung transplants reported compared to the numbers prior to the adoption of elexacaftor/tezacaftor/ivacaftor. In 2023, there were 61 lung transplants reported.



## **MENTAL HEALTH**

PERCENT OF PEOPLE WITH CF AGE 12 YEARS AND OLDER WITH REPORTED DEPRESSION OR ANXIETY










#### **EDUCATION**




of adults with CF have a college degree.

## **NUTRITIONAL STATUS**

Over the last 20 years, the percentage of people with CF who are overweight or obese has increased — from 10% to 21% among children with CF and from 18% to 42% among adults.



## NUMBER OF PEOPLE WITH CF IN THE PATIENT REGISTRY



61

YEARS

2019-2023

Among people with CF born 2019-

individual variability. The median

2023, half are predicted to live to 61+ years. However, this does not reflect

survival is lower for those ineligible for

modulators by possibly over a decade.




CYSTIC FIBROSIS FOUNDATION 4550 Montgomery Ave., Suite 1100N Bethesda, MD 20814 800-FIGHT-CF

SOURCE DATA Cystic fibrosis patients under care at CF Foundation-accredited care centers in the United States, who consented to have their data entered.

SUGGESTED CITATION 2023 Cystic Fibrosis Foundation Patient Registry Highlights Bethesda, Maryland ©2024 Cystic Fibrosis Foundation

### SURVIVAL



**Five-Year Increments**